The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study

Mon, 23rd Nov 2020 19:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ReNeuron Group PLC - Bridgend, Wales-based cell-based therapeutics - Intends to raise gross proceeds up to GBP13.9 million via placing with institutional and other investors alongside up to GBP1.1 million direct subscription. Both will be priced at 70 pence per share with proceeds allowing ReNeuron "to deliver extended clinical data from its ongoing retinitis pigmentosa phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully." Also announces up to GBP2. million open offer.

----------

Lekoil Ltd - African oil exploration and production firm with interests in Nigeria and offshore Namibia - Announces that 15.4% stakeholder Lynchwood Nominees Ltd has requisitioned an extraordinary general meeting where it seeks to oust Chair Mark Simmonds and appoint Michael Ajukwu, Thomas Richardson and George Maxwell to the Lekoil board. Requisition further proposes special resolutions relating to restriction to bee place on the affairs of Lekoil Ltd (Nigeria), Lekoil's principal subsidiary. Leoil in "advanced talks" with new nominated advisor, who will review resolutions proposed. This is expected to extend the due diligence process needed before new nomad is appointed, increasing the risk of share delisting.

----------

Versarien PLC - Cheltenham-based advanced materials engineer - Announces interim results reporting extension and will now release its interim results for the six months ended September 30 by January 31 at the latest. This is in line with Covid-19 guidance allowing for a 1-month extension for reporting interim financial results.

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Enters into unsecured three-year GBP30 million term loan facility agreement with Royal Bank of Scotland International Ltd, intended to be fully drawn. Loan will represent approximately 10% of company's net asset value once drawn. Appoints Martin Currie Fund Management Ltd as alternative investment fund manager, having "decided that it is now in the best interests of the company that it has a modest level of structural gearing consistent with the gearing policy".

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Notes that its Liver Surface Nodularity software application is now CE Mark approved. LSN algorithms process CT images of livers to assess nodules on the surface, conducting a virtual biopsy. This confirms that the LSN meets essential requirements of the European Medical Devices Directive. Follows US Food & Drug Administration's granting of 510(k) market clearance for LSN software earlier in November. IQ-AI says: "These recent regulatory milestones permit IQ-AI's subsidiary, Imaging Biometrics, LLC, the manufacturer of record for LSN, to market and sell the software to the world's two most prominent healthcare markets."

----------

Braemar Shipping Services PLC - London-based provider of technical expertise and professional marine and energy services - Says AqualisBraemar ASA will acquire LOC Group. Baemar Shipping holds an approximately 27% stake in AqualisBraemar, which is an associate company. Combination is intended to create "leading global independent offshore energy and marine consultancy". "Braemar believes this expansion will help generate further momentum for AQB, building on the strong progress stated in its Q3-2020 results, and has therefore shown its support and given the AQB board undertakings to vote in favour of the transaction." Braemar Shipping to hold around 21% stake in enlarged group.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.